Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

October 30, 2024

Study Completion Date

November 30, 2024

Conditions

Overweight and Obesity

Interventions

DRUG

HDM1002 100 mg QD

HDM1002 tablets 100mg daily, 12weeks

DRUG

HDM1002 200 mg QD 12weeks

HDM1002 tablets 200mg daily, 12weeks

DRUG

HDM1002 400 mg QD 12weeks

HDM1002 tablets 400mg daily, 12weeks

DRUG

Placebo

Matching placebo will be provided

All Listed Sponsors

lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY